SCHEMBL1798657

SCHEMBL1798657

CC(C)(C)OC(=O)c1c(-c2ccccc2)csc1NC(=O)CCCCC(=O)Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.48
POLB P06746 1/20 0.48
PTPN1 P18031 4/20 0.45
PTPRC P08575 2/20 0.45
PTPN2 P17706 2/20 0.45
PTPA Q15257 2/20 0.45
PTPRF P10586 1/20 0.45
ALDH1A1 P00352 5/20 0.45
TP53 P04637 1/20 0.44
KDM4E B2RXH2 2/20 0.43
GAA P10253 1/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 3/20 0.43
ANO1 Q5XXA6 3/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1796957 0.99 RAB9A (0.47) RAB9APOLBPTPN1PTPRCPTPN2
SCHEMBL1796283 0.94 RAB9A (0.47) RAB9APOLBPTPN1PTPRCPTPN2
SCHEMBL1796954 0.92 POLB (0.46) RAB9APOLBPTPN1PTPRCPTPN2
SCHEMBL1796259 0.90 RAB9A (0.52) RAB9APOLBPTPN1PTPRCPTPN2
SCHEMBL1796981 0.89 RAB9A (0.51) RAB9APOLBPTPN1PTPRCPTPN2
SCHEMBL1795848 0.88 ANO1 (0.54) ANO1MEN1KMT2A
SCHEMBL1800530 0.86 POLB (0.52) RAB9APOLBALDH1A1TP53KDM4E
SCHEMBL1799695 0.85 RAB9A (0.51) RAB9APOLBPTPN1PTPRCPTPN2
SCHEMBL1801503 0.85 ANO1 (0.50) RAB9APOLBALDH1A1ANO1MEN1
SCHEMBL1799358 0.84 RAB9A (0.62) RAB9APOLBPTPN1PTPRCPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US claimed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US claimed
US-10092537-B2 Use for PAI-1 inhibitor RENASCIENCE CO., LTD. (JP) 2018-10-09 US disclosed
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2016-06-09 US disclosed
EP-2990057-A1 NOVEL USE FOR PAI-1 INHIBITOR Renascience Co., Ltd. (JP) 2016-03-02 EP disclosed
US-7951806-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2011-05-31 US disclosed
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO., LTD. (JP) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160158188-A1 NOVEL USE FOR PAI-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 RAB9A 2760/4885POLB 2824/4885PTPN1 3814/4885
US-20090124620-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 RAB9A 2391/4885POLB 2674/4885PTPN1 853/4885
US-10092537-B2 Use for PAI-1 inhibitor SERPINE1, SERPINC1, SERPINB1 RAB9A 2814/4885POLB 2556/4885PTPN1 4113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.